OptiBiotix, quoted on AIM under the code OPTI, develops and sells microbiome-focused ingredients and products. Its main commercial ingredient is SlimBiome, used in weight-management products sold by partners, alongside WellBiome. It is also developing SweetBiotix, a second-generation fibre-based sweetener, and holds investments in other …
GENinCode develops genetic tests designed to assess an individual's risk of cardiovascular disease and other conditions. Its products include CARDIO inCode-Score, a polygenic risk test for coronary artery disease, and LIPID inCode, which the company says has been onboarded at more than 80 US …
Aptamer develops Optimer binders, synthetic molecules that the company describes as next-generation alternatives to antibodies. They can be used in diagnostics, laboratory tools and therapeutic programmes. The group earns fees from development projects with partners and is seeking to turn successful projects into licences …
Hemogenyx's lead product is HG-CT-1, a chimeric antigen receptor T-cell (CAR-T) therapy targeting FLT3 for patients with relapsed or refractory acute myeloid leukaemia (AML). Its Phase I trial site is MD Anderson Cancer Center in the US. The company is also developing CDX, a …
Cambridge Nutritional Sciences develops and sells tests that help practitioners and patients identify food sensitivities. Its largest product is FoodPrint, an IgG antibody food sensitivity test, alongside Food Detective, a rapid point-of-care test, and CNSLab, a UK laboratory testing service. CNSLab testing volumes rose …
RUA Life Sciences Plc (LSE:RUA) advanced 3.51% on 5 October 2026, placing the stock among the session’s notable UK gainers.
Arecor Therapeutics PLC (LSE:AREC) advanced 3.45% on 5 October 2026, placing the stock among the session’s notable UK gainers.
• TheraCryf appointed an Australian clinical research partner to support Phase 1 preparations for Ox-1.
On 30 September Verici released unaudited interim results for the six months to 30 June 2026. Tutivia, its blood test designed to help detect early acute rejection after kidney transplant, delivered testing revenue growth of 53% year on year. The number of US transplant …
Aptamer Group Plc (LSE:APTA), the developer of next-generation synthetic binders for the life sciences industry, ended 2 October 2026 up 4.84%. The move kept the micro-cap biotech in view among investors tracking UK-listed life sciences stocks, where small share price moves can reflect shifting …